Everolimus + Ranibizumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Choroidal Neo-Vascular Age-onset Macular Degeneration
Conditions
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
Trial Timeline
Feb 1, 2009 → —
NCT ID
NCT00857259About Everolimus + Ranibizumab
Everolimus + Ranibizumab is a phase 2 stage product being developed by Novartis for Choroidal Neo-Vascular Age-onset Macular Degeneration. The current trial status is terminated. This product is registered under clinical trial identifier NCT00857259. Target conditions include Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00857259 | Phase 2 | Terminated |
Competing Products
20 competing products in Choroidal Neo-Vascular Age-onset Macular Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| ranibizumab | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| ranibizumab 0.5mg | Novartis | Phase 2 | 52 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal injection ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 1/2 | 41 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 77 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Intravitreal Pegaptanib | Pfizer | Pre-clinical | 22 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Regeneron Pharmaceuticals | Pre-clinical | 22 |